ADC Therapeutics SA (ADCT) Tops Q4 EPS by 20c
Tweet
Share
E-mail
Get Alerts ADCT Hot Sheet
Join SI Premium – FREE
ADC Therapeutics SA (NYSE: ADCT) reported Q4 EPS of ($0.09), $0.20 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $23.06 million versus the consensus estimate of $19.11 million.
For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla readies August launch of CyberCab - The Information
- L. Paris Watts-Stanfield resigns from IDEX Corp. board
- ResMed names Carol Burt as lead director as Ron Taylor retires
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
